Yong Hui Ahn, MD
Internal Medicine · Slc, UTNPI 1427023571
Payments from drug & device makers
Across 238 payments — averaging $1992.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$445K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$14K
- Acadia Pharmaceuticals Inc$12K
- AbbVie$502
- Amgen$303
- Astellas Pharma US Inc$252
- plus $2K from 33 others
Across 2 payments — averaging $6325.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$13K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 41 | $444,798 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $13,970 |
| Acadia Pharmaceuticals Inc | 7 | $12,218 |
| AbbVie(2 entities) | 23 | $502 |
| Amgen | 18 | $303 |
| Astellas Pharma US Inc | 15 | $252 |
| Merck | 15 | $234 |
| Novo Nordisk | 14 | $227 |
| Lilly USA, LLC | 11 | $191 |
| Boehringer Ingelheim | 7 | $152 |
| AstraZeneca | 10 | $144 |
| Amarin Pharma, Inc. | 8 | $143 |
| Sanofi-aventis U.S. LLC | 9 | $128 |
| Pfizer | 7 | $112 |
| GSK | 8 | $110 |
| Insmed, Inc. | 5 | $75 |
| Johnson & Johnson | 4 | $61 |
| Bayer | 3 | $50 |
| Sanofi Pasteur Inc. | 3 | $47 |
| Neuronetics, Inc. | 1 | $40 |
| Alkermes, Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Novartis | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Seqirus USA Inc | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Romark Laboratories, LC | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Boston Scientific | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Mannkind Corporation | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Medtronic | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$474,200 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Slc
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
- Joseph WoolleySaint George$3.6M
- Justin MansfieldOgden$3.1M
- Michael KillpackSandy$2M
- Cuper Martinez SantibanezWest Valley City$1M
- Joshua OaksBountiful$973K
- Brandon WebbSalt Lake City$544K
- Larry StakerSalt Lake City$441K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.